Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT2 | P23786 | 1/20 | 0.71 |
| ▸ | CPT1A | P50416 | 1/20 | 0.71 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.57 |
| ▸ | MEN1 | O00255 | 5/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CASP3 | P42574 | 2/20 | 0.50 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.50 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2828830 | 0.89 | CPT2 (0.81) | CPT2CPT1ACPT1BMAPTLMNA | |
| SCHEMBL2825208 | 0.89 | CPT2 (0.80) | CPT2CPT1ACPT1BMAPTLMNA | |
| SCHEMBL2827257 | 0.87 | CPT2 (0.67) | CPT2CPT1ACPT1BMAPTLMNA | |
| SCHEMBL2826875 | 0.85 | CPT2 (0.79) | CPT2CPT1ACPT1BMAPTLMNA | |
| SCHEMBL2828878 | 0.85 | LMNA (0.60) | CPT2CPT1ACPT1BMAPTLMNA | |
| SCHEMBL2824710 | 0.84 | THRB (0.81) | MAPTLMNASMN1; SMN2THRBKMT2A | |
| SCHEMBL2823121 | 0.84 | CPT2 (0.64) | CPT2CPT1ACPT1BMAPTLMNA | |
| SCHEMBL2828026 | 0.83 | CPT1A (1.00) | CPT2CPT1ACPT1BMAPTLMNA | |
| SCHEMBL27723425 | 0.83 | RAB9A (0.54) | CPT2CPT1ACPT1BMAPTLMNA | |
| SCHEMBL5326147 | 0.80 | LMNA (0.65) | MAPTLMNASMN1; SMN2THRBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120232104-A1 | NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS | BLEICHER KONRAD (DE) | 2012-09-13 | — | — | US | claimed |
| CN-101189210-B | Sulfonamide derivatives useful as liver carnitine palmitoyl transferase (L-CPTl) inhibitors | HOFFMANN LA ROCHE | 2012-06-06 | — | — | CN | claimed |
| US-20110319438-A1 | NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS | BLEICHER KONRAD (DE) | 2011-12-29 | — | — | US | claimed |
| US-20100144762-A1 | NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS | BLEICHER KONRAD | 2010-06-10 | — | — | US | claimed |
| US-7723538-B2 | enzyme inhibitors of membrane-bound carnitine-dependent palmitoyltransferases (CPTs); inhibit gluconeogenesis and therefore counteract hyperglycemia; 4-(3-Benzenesulfonylamino-benzoylamino)-benzoic acid | HOFFMANN-LA ROCHE INC. (US) | 2010-05-25 | — | — | US | claimed |
| EP-1891001-B1 | SULFONAMIDE DERIVATIVES USEFUL AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTl) INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-05-05 | — | — | EP | claimed |
| CN-101189210-A | Sulfonamide derivatives useful as liver carnitine palmitoyl transferase (L-CPTl) inhibitors | HOFFMANN LA ROCHE (CH) | 2008-05-28 | — | — | CN | claimed |
| EP-1891001-A1 | SULFONAMIDE DERIVATIVES USEFUL AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTl) INHIBITORS | F. Hoffmann-Roche AG (CH) | 2008-02-27 | — | — | EP | claimed |
| WO-2006131452-A1 | SULFONAMIDE DERIVATIVES USEFUL AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTl) INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-14 | — | — | WO | claimed |
| US-20060276494-A1 | Novel sulfonamides as L-CPT1 inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-07 | — | — | US | claimed |
| US-20240207270-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | WAVEBREAK INC (US) | 2024-06-27 | — | — | US | disclosed |
| WO-2022212568-A9 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | 1BASE PHARMACEUTICALS, LLC (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2022212568-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | 1BASE PHARMACEUTICALS, LLC (US) | 2022-10-06 | — | — | WO | disclosed |
| US-20120232104-A1 | NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS | BLEICHER KONRAD (DE) | 2012-09-13 | — | — | US | disclosed |
| CN-101189210-B | Sulfonamide derivatives useful as liver carnitine palmitoyl transferase (L-CPTl) inhibitors | HOFFMANN LA ROCHE | 2012-06-06 | — | — | CN | disclosed |
| EP-1891001-B1 | SULFONAMIDE DERIVATIVES USEFUL AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTl) INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-05-05 | — | — | EP | disclosed |
| CN-101189210-A | Sulfonamide derivatives useful as liver carnitine palmitoyl transferase (L-CPTl) inhibitors | HOFFMANN LA ROCHE (CH) | 2008-05-28 | — | — | CN | disclosed |
| EP-1891001-A1 | SULFONAMIDE DERIVATIVES USEFUL AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTl) INHIBITORS | F. Hoffmann-Roche AG (CH) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006131452-A1 | SULFONAMIDE DERIVATIVES USEFUL AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTl) INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-14 | — | — | WO | disclosed |
| US-20060276494-A1 | Novel sulfonamides as L-CPT1 inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276494-A1 | Novel sulfonamides as L-CPT1 inhibitors | CPT1A, CPT1B, CPT2 | CPT2 3/4885CPT1A 1/4885CPT1B 2/4885 |
| US-20120232104-A1 | NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS | CPT1A, CPT1B, CPT2 | CPT2 3/4885CPT1A 1/4885CPT1B 2/4885 |
| US-20240207270-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | CPT2, PC, SREBF2 | CPT2 1/4885CPT1A 15/4885CPT1B 50/4885 |
| US-20100144762-A1 | NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS | CPT1A, CPT1B, CPT2 | CPT2 3/4885CPT1A 1/4885CPT1B 2/4885 |
| US-20110319438-A1 | NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS | CPT1A, CPT1B, CPT2 | CPT2 3/4885CPT1A 1/4885CPT1B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.